BioCentury
ARTICLE | Clinical News

Sosei, Allergan to delay trials of dementia candidate

September 21, 2018 5:38 PM UTC

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the compound. The investigation will delay by at least six months the start of planned Phase II trials in dementia with Lewy bodies (DLB) and Alzheimer's disease.

Sosei said it no longer expects to receive a milestone payment from Allergan next year relating to progress of the muscarinic acetylcholine receptor M1 (CHRM1; HM1) agonist in AD. Sosei declined to disclose the milestone amount...